{"ticker": {"uuid": "a81c17d2-0767-4275-8281-77477229c0e3", "symbol": "DMII", "name": "Drugs Made In America Acquisition II Corp. Ordinary Shares", "exchange": "NASDAQ", "country": "US", "sector": "Financial Services", "industry": "Shell Companies"}, "articles": [{"title": "Drugs Made In America Acquisition (NASDAQ:DMAA) Trading Down 0.1% - Here's What Happened", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNM2FXbkJYaDJZeGhjU3VrelVXa3NHZ2dSam16MzYzNk1QdmRsbU1WSmNTbU1oX2tuTWRLaFFxWG1TYmFlMDNqVW5UOFlHTFgyQU1EQWowZ2xRUjJuVmlCdVd3SXVSOHhSWXBNRTFWXzFQdTdBZEF1WjFmMldJekwycWRyWXB0akd6YVlEd2JjSnB4TG1EXzVvazUxRnFsTW43TWlOc2tpdE51dm5lajdyOGkzaHJDNFFoeEFLUnNNS3NXWFN2SWZXMTM3RmlkVWM?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-11T13:28:09+00:00", "published_display": "11 Jul 2026 13:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Drugs Made In America Acquisition Corp. \u2013 NASDAQ:DMAAR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPTjBjZHNSTFJCN2M5TFBmNzJvN1Fjc04yVTgzcjhra2RRd0U0STNZb1NwVkFDTXR1NmRNRVl1MnJndVptRUt2UFh3ekxkZmxsOWY5QmZ3VDNYV1ZGV1FEc0hJb0s1Y3h1WWQ2UGtqWTdOUzJXT1ZtMElZbTU4emxmc25fTXZ4QTc5cm9Bd25FUjVnYjV5eHF3THVfTlVWNy1iRndz?oc=5", "source_name": "TradingView", "published_at": "2026-07-07T02:32:22+00:00", "published_display": "07 Jul 2026 02:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tandem Diabetes (TNDM) Shares Are Sliding Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOX3pyOWxmc05WS1NBdmV3anVMRG9OSkd1OU1RNnFCVWkxcTVtdWRWTG1jVERPaVExQlZaa09kdWNCZHk2a3JjUFpfVmpvSEptVUFXV3JLYWVjWnY0UVdXTUJCR2UzYTV6ODFyVUNhNE5raDBTelhSNmF4ZExCazdURjctU05mdkh3LUpXUC10dmgwUDZZUkN3eFlKWFUzNUk1dTNicTVIRnZkUV9EUF9j?oc=5", "source_name": "TradingView", "published_at": "2026-06-30T18:56:21+00:00", "published_display": "30 Jun 2026 18:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Drugs Made In America Acquisition II Corp. \u2013 NASDAQ:DMII", "summary": "The article focuses on the \"Price to sales forward\" metric for Drugs Made In America Acquisition II Corp. (NASDAQ: DMII). It provides basic financial and market information for the company, indicating that the market is currently closed with no trades. The content appears to be a", "url": "https://www.tradingview.com/symbols/NASDAQ-DMII/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T13:11:57", "published_display": "29 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMII Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article provides a financial overview of Drugs Made In America Acquisition II Corp (DMII), detailing its profitability ratios, including Return on Equity, and comparing its market capitalization with competitors like RMR and BCSS. It notes that DMII's gross, operating, and n", "url": "https://intellectia.ai/en/stock/DMII/financials", "source_name": "Intellectia AI", "published_at": "2026-06-27T22:10:05", "published_display": "27 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Drugs Made In America Acquisition II Corp. \u2013 NASDAQ:DMIIR", "summary": "This article provides financial information for Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR), specifically focusing on its price-to-book forward ratio. The content appears to be a stub or a section from a larger financial data platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-DMIIR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T12:08:54", "published_display": "26 Jun 2026 12:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tandem Diabetes (NASDAQ: TNDM) Rule 144 notice to sell 361 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQUkdpSjdvbTZBNnd4Yng4T1hjdWhNdnROUU9FeEE3MTlUNGZIRldsc1ZEX3loWEJWaWNVQzBFVXdCak5HUWxDOEF1M2J5LThZeWFCUlBya04xSjlwRXVrWmlTM244ZTJxeXN1MG9Qal9RalVMRDYyZnJRWk1pamZ1dHVPT1haVlZjUGhGeW1DUng1UWxCUUJRNjlXOW5OT0lIRlJ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. (DMII) Holds Steady Near $10.07, Trading in Tight Range - Risk Parity Rebalance", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQVG5UMmJucUJ2TXdwaUszQkJXZWNteEs1N2JIVm40UDFDVjNBcDRIVE8xYl9hV0pCVGtWSTdSUmZuVnBWbHA1S0RNUTh4R2xMb3ByY3JnTVE4Z1h3VWkxcXcwQlU2UUJhYUNlWGRTcFNTVjlJVEhyc1dPTzhfcDVScDIxMEpRMnZjMlpMWndTU2c4YWk5UnFwRWw1REJTdTUzV3h4eTZ6ZmhmSUZGeDlBTi1kM1ZHS0UweUpwZkV6M3UyYWlNcjN6YTUxR3hsUFBDMHMtMXpnVzBoc0ph?oc=5", "source_name": "B\u00f6l\u00fcm Sonu Canavar\u0131", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. Unit (DMIIU) Holds Steady Amid Extended Consolidation - Money Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQZlpGX3d3N3ZScDNVQXlwbzVfVEp0RmZxMjh1TlU5TFRHY2hXVUVlVkJyeEQwQ3AtZmtLRllfcUZTYUk1MUNzdDd5Y29GeF9zSUpNbkVrTWxNelcyVGpHd1JiM1pZb0FzVXU4UDZYb1dIUGtvMkMxQ3FVSHdDc3RncFFGYnJkZkUzVFhyOVJCdzdTODNSV3h4cDdGTFd2MkNDVTd2TW5MTVZySGpGcVVaMkw4WHRTQmJOemtjLWlTN1F0LWlFQTUtUi1BYlFzZFc5WEE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HEIGHTS CAPITAL MANAGEMENT, INC's Drugs Made In America Acquisition II Corp(DMIIU) Holding History", "summary": "This article details HEIGHTS CAPITAL MANAGEMENT, INC's historical holdings in Drugs Made In America Acquisition II Corp (DMIIU). As of March 31, 2026, the firm holds 0 shares of DMIIU, having made one purchase and one sale of 519,400 shares each, resulting in an estimated gain of", "url": "https://www.gurufocus.com/guru-portfolio/HEIGHTS%20CAPITAL%20MANAGEMENT,%20INC/DMIIU", "source_name": "GuruFocus", "published_at": "2026-05-15T22:09:31", "published_display": "15 May 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tandem Diabetes (TNDM) Shares Are Trading Lower Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOTEY4U2JLc0E4T0hMcHV5R293WEhSTjNDb2xWSGg5X0hpSEsxVXJ4dzI4UmIyaEI5NU1seW1PcUllcVdPTG8zc2pGdFlvZDk4ZFJRWUZHRG9aSlNIeVBUVGhtVFlneFlYM1lMSnoxTHVvRVFDd005c3VjRFdlRTFPWEppTldPNmk5bzUxNVhta1BTTUg4NEIxUWNXZHltUzVVNHluSmRsU0pCQTR1TXR6Sk42dXpRTld6eUdJ?oc=5", "source_name": "StockStory", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Updates Executive Compensation Agreements", "summary": "Drugs Made In America Acquisition II Corp. (DMII) has updated its executive compensation agreements. Saleem Elmasri, CFO, will now receive 175,000 ordinary shares, while Roger Bendelac, CEO, will receive a monthly salary of $4,500 and 250,000 ordinary shares upon a definitive agr", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1603715/drugs-made-in-america-acquisition-updates-executive-compensation-agreements/", "source_name": "The Globe and Mail", "published_at": "2026-04-29T23:09:57", "published_display": "29 Apr 2026 23:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America (NASDAQ: DMAA) details SPAC cash, LOI and risks", "summary": "Drugs Made In America Acquisition Corp. (DMAA), a SPAC, has filed its annual report detailing its search for a merger target. The company currently holds $231.15 million in its trust account and reported a net income of $5.94 million in 2025 from interest on these investments. DM", "url": "https://www.stocktitan.net/sec-filings/DMAA/10-k-drugs-made-in-america-acquisition-corp-files-annual-report-77c544c456a1.html", "source_name": "Stock Titan", "published_at": "2026-04-15T21:40:00", "published_display": "15 Apr 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II (DMII) logs $4.2M income, flags going-concern risk", "summary": "Drugs Made In America Acquisition II (DMII), a blank check company, reported a net income of $4.187 million for 2025, primarily from interest on its $500 million trust account investments. However, the company faces substantial doubt about its ability to continue as a going conce", "url": "https://www.stocktitan.net/sec-filings/DMII/10-k-drugs-made-in-america-acquisition-ii-corp-files-annual-report-db37da9991f3.html", "source_name": "Stock Titan", "published_at": "2026-04-15T20:08:51", "published_display": "15 Apr 2026 20:08", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. Auditor Raises 'Going Concern' Doubt", "summary": "Drugs Made In America Acquisition II Corp. (DMII) recently had its auditor, Malone & Bailey, PLLC, express doubt about the company's ability to continue as a going concern. This assessment was made after the company filed its 10-K report on April 15, 2026, for the fiscal year end", "url": "https://www.marketscreener.com/news/drugs-made-in-america-acquisition-ii-corp-auditor-raises-going-concern-doubt-ce7f59dedc8ef422", "source_name": "www.marketscreener.com", "published_at": "2026-04-12T19:10:17", "published_display": "12 Apr 2026 19:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made in America Acquisition Corp. signs LOI for de-SPAC with Power Analytics", "summary": "Drugs Made in America Acquisition Corp. (NASDAQ:DMAA) announced it has signed a letter of intent for a de-SPAC transaction with Power Analytics Global Corp., valuing the target company at approximately $1.0 billion. The transaction is subject to further negotiation and due dilige", "url": "https://www.investing.com/news/sec-filings/drugs-made-in-america-acquisition-corp-signs-loi-for-despac-with-power-analytics-93CH-4603239", "source_name": "Investing.com", "published_at": "2026-04-09T09:12:00", "published_display": "09 Apr 2026 09:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. Unit (DMIIU) Competitors", "summary": "This article provides a detailed comparison of Drugs Made In America Acquisition II Corp. Unit (DMIIU) with numerous competitors in the Financial Services sector. It presents a peer comparison table with financial metrics like price, market cap, P/E ratio, EPS, and dividend yield", "url": "https://meyka.com/stock/DMIIU/peers/", "source_name": "Meyka", "published_at": "2026-04-09T01:09:11", "published_display": "09 Apr 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. enters $300,000 convertible note agreement", "summary": "Drugs Made In America Acquisition II Corp. (DMIIU, DMII, DMIIR) has entered into a $300,000 interim convertible note agreement with Alpha Multi Family Office, carrying no interest and maturing in nine months. This note allows Alpha Multi Family Office to convert the principal int", "url": "https://ca.investing.com/news/sec-filings/drugs-made-in-america-acquisition-ii-corp-enters-300000-convertible-note-agreement-93CH-4549250", "source_name": "Investing.com Canada", "published_at": "2026-04-04T22:39:18", "published_display": "04 Apr 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. Announces $1.4 Million Convertible Notes Financing Agreement with Alpha Multi Family Office", "summary": "Drugs Made In America Acquisition II Corp. has secured a $1.4 million convertible notes financing agreement from S.E.E Capitals Ltd., with the funds allocated for operational and regulatory costs. The agreement includes provisions for potential share dilution if the investor conv", "url": "https://www.minichart.com.sg/2026/04/04/drugs-made-in-america-acquisition-ii-corp-announces-1-4-million-convertible-notes-financing-agreement-with-alpha-multi-family-office/", "source_name": "Minichart", "published_at": "2026-04-04T22:09:34", "published_display": "04 Apr 2026 22:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America II Issues Interim Convertible Note", "summary": "Drugs Made In America Acquisition II Corp. (DMII) has issued a new $300,000 interim convertible note on March 30, 2026, building upon a previous $150,000 bridge note from March 11, 2026, as part of a $1.4 million financing plan. This new note, maturing in nine months with no inte", "url": "https://www.tipranks.com/news/company-announcements/drugs-made-in-america-ii-issues-interim-convertible-note", "source_name": "TipRanks", "published_at": "2026-04-03T21:12:55", "published_display": "03 Apr 2026 21:12", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Finalizes $1.4M Notes Deal, Adds $300K Interim Convertible", "summary": "Drugs Made In America Acquisition II (DMII) has finalized a definitive agreement with Alpha Multi Family Office for a $1.4 million convertible notes financing. Concurrently, it issued a new $300,000 interim convertible note to provide immediate liquidity. Both agreements aim to s", "url": "https://www.tradingview.com/news/tradingview:9badd5a98b635:0-drugs-made-in-america-acquisition-ii-finalizes-1-4m-notes-deal-adds-300k-interim-convertible/", "source_name": "TradingView", "published_at": "2026-04-03T20:42:55", "published_display": "03 Apr 2026 20:42", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$300K zero\u2011interest note backs Drugs Made In America II (NASDAQ: DMII)", "summary": "Drugs Made In America Acquisition II Corp. (DMII) secured a new $300,000 zero-interest Interim Convertible Note from Alpha Multi Family Office, part of a contemplated $1.4 million financing. This note matures in nine months and can convert into shares at a 35% discount post-merge", "url": "https://www.stocktitan.net/sec-filings/DMII/8-k-drugs-made-in-america-acquisition-ii-corp-reports-material-event-602970d519a7.html", "source_name": "Stock Titan", "published_at": "2026-04-03T20:39:55", "published_display": "03 Apr 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made in America Acquisition II Delays Annual Filing", "summary": "Drugs Made in America Acquisition II Corp. (DMII) has announced a delay in filing its Form 10-K for the fiscal year ended December 31, 2025, due to complexities in compiling required financial statements. The company anticipates filing by April 15, 2026, and does not foresee sign", "url": "https://www.tipranks.com/news/company-announcements/drugs-made-in-america-acquisition-ii-delays-annual-filing", "source_name": "TipRanks", "published_at": "2026-04-01T23:39:58", "published_display": "01 Apr 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMII (NASDAQ: DMII) files 12b-25\u2014expects to file 10-K by Apr 15, 2026", "summary": "Drugs Made in America Acquisition II Corp. (DMII) has filed a Form 12b-25 with the SEC, indicating that it will be submitting its Form 10-K for the fiscal year ended December 31, 2025, later than the due date. The company stated that compiling the required financial statements an", "url": "https://www.stocktitan.net/sec-filings/DMII/nt-10-k-drugs-made-in-america-acquisition-ii-corp-sec-filing-1ea9598c3e77.html", "source_name": "Stock Titan", "published_at": "2026-04-01T20:11:11", "published_display": "01 Apr 2026 20:11", "sentiment": "negative", "sentiment_pct": 37, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. - Right (NQ: DMIIR)", "summary": "This article provides a brief overview of Drugs Made In America Acquisition II Corp. - Right (DMIIR) stock, including its current price, trading volume, and performance metrics. It lists the stock at $0.0800, unchanged, with its last trade recorded on April 1, 2026, at 3:20 PM ED", "url": "https://markets.financialcontent.com/stocks/quote?Symbol=537%3A2578439971", "source_name": "FinancialContent", "published_at": "2026-04-01T19:39:59", "published_display": "01 Apr 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Drugs Made In America Acquisition II Corp. Unit (DMIIU) Stock Down Today?", "summary": "Drugs Made In America Acquisition II Corp. Unit (DMIIU) stock is currently down -0.10% at $10.02, indicating a negative investor sentiment. The stock is trading below both its 50-day and 200-day moving averages, suggesting short-term and long-term weakness. Meyka's AI assigns DMI", "url": "https://meyka.com/stock/DMIIU/why-stock-down-today/", "source_name": "Meyka", "published_at": "2026-03-24T11:08:58", "published_display": "24 Mar 2026 11:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) Stock Down Today?", "summary": "Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) stock is down 0.10% today, trading at $9.96 with significantly lower than average trading volume. The stock is below its 50-day moving average but above its 200-day moving average, suggesting short-term weakness bu", "url": "https://meyka.com/stock/DMII/why-stock-down-today/", "source_name": "Meyka", "published_at": "2026-03-23T21:08:58", "published_display": "23 Mar 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "14,375,000 Ordinary Shares of Drugs Made In America Acquisition II Corp. are subject to a Lock-Up Agreement Ending on 23-MAR-2026.", "summary": "Approximately 14,375,000 ordinary shares of Drugs Made In America Acquisition II Corp. (DMII) are subject to a lock-up agreement that expires on March 23, 2026. This lock-up period began on September 24, 2025, and restricts the sale or transfer of these shares by the company's sp", "url": "https://www.marketscreener.com/news/14-375-000-ordinary-shares-of-drugs-made-in-america-acquisition-ii-corp-are-subject-to-a-lock-up-ag-ce7e5edcdb8cf72d", "source_name": "www.marketscreener.com", "published_at": "2026-03-23T00:10:39", "published_display": "23 Mar 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMII Stock Price, News & Analysis", "summary": "Drugs Made In Amer Acq Ii (DMII) is a blank check company listed on NASDAQ with a market capitalization of $653.1M. The stock last traded at $9.96, showing a 0.8% gain over the past year. Recent SEC filings include a planned $1.4M convertible note funding and a CEO change due to ", "url": "https://www.stocktitan.net/overview/DMII/", "source_name": "Stock Titan", "published_at": "2026-03-18T18:39:23", "published_display": "18 Mar 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prudential Earnings: Headline Numbers Make the Market Skeptical; Shares Fairly Valued", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOLXpWLThmYURNcnJBLXZQNTlRUy1NSmQ4NkVVX0pQRzlfUFFtVFJkNDJqN1FFYWZLWS1xSmd5S3dNUU42cjFLOUdiWTkxdXhvZXg1UlFtZmtVZG1qN2w4QWxXZEJsbFJ2QUQtVUIxMWJ4Z1l3djBiNFp3MEdhbkh6cUtlWVB5b2RNZXZudmhPbWI3RkF0NmhxdF9aQmppbUFHOThtZDlBU3Vsak9fX0pKUGotdHNBaDkzODRZbGdUUVc?oc=5", "source_name": "Morningstar", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America II (NASDAQ: DMII) plans $1.4M convertible note funding", "summary": "Drugs Made In America Acquisition II Corp. (NASDAQ: DMII) has entered into an agreement for up to $1.4 million in convertible note funding with Alpha Multi Family Office. The initial tranche involved an unsecured, zero-interest Bridge Note for $150,000, convertible at a 35% disco", "url": "https://www.stocktitan.net/sec-filings/DMII/8-k-drugs-made-in-america-acquisition-ii-corp-reports-material-event-0798a7bf46b6.html", "source_name": "Stock Titan", "published_at": "2026-03-18T03:09:55", "published_display": "18 Mar 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Secures $150,000 Convertible Bridge Note From Alpha Multi Family Office", "summary": "Drugs Made In America Acquisition II (DMII) has secured a $150,000 unsecured convertible bridge note from Alpha Multi Family Office to cover near-term transaction costs. The nine-month, zero-interest note can convert into post-combination company shares at a 35% discount upon bus", "url": "https://www.tradingview.com/news/tradingview:7e76831afc085:0-drugs-made-in-america-acquisition-ii-secures-150-000-convertible-bridge-note-from-alpha-multi-family-office/", "source_name": "TradingView", "published_at": "2026-03-17T20:09:55", "published_display": "17 Mar 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMIIR - AI Stock Analysis", "summary": "This article provides an AI-powered stock analysis for Drugs Made In America Acquisition II Corp. Right (DMIIR). The AI model gives DMIIR an overall forecast score of 51/100 (C+), indicating normal performance with weak confidence in its potential. While its financial and fundame", "url": "https://meyka.com/stock/DMIIR/analysis/", "source_name": "Meyka", "published_at": "2026-03-16T03:39:23", "published_display": "16 Mar 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. appoints new CEO after sponsor repayment issue", "summary": "Drugs Made In America Acquisition II Corp. (NASDAQ:DMIIU) has appointed Roger Bendelac as its new CEO, following the resignation of Lynn Stockwell. Stockwell's resignation was requested after the company discovered its sponsor had over-withdrawn funds from the working capital acc", "url": "https://www.investing.com/news/sec-filings/drugs-made-in-america-acquisition-ii-corp-appoints-new-ceo-after-sponsor-repayment-issue-93CH-4547284", "source_name": "Investing.com", "published_at": "2026-03-08T22:51:22", "published_display": "08 Mar 2026 22:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO exits Drugs Made In America (NASDAQ: DMAA) after affiliate fund withdrawals", "summary": "Drugs Made In America Acquisition Corp. (DMAA) announced the resignation of CEO Lynn Stockwell and the appointment of Roger Bendelac following financial discrepancies involving an affiliated SPAC's working capital account. The affiliate's sponsor withdrew $1,100,000 and had an ov", "url": "https://www.stocktitan.net/sec-filings/DMAA/8-k-drugs-made-in-america-acquisition-corp-reports-material-event-100e6bb0dc73.html", "source_name": "Stock Titan", "published_at": "2026-03-08T22:51:22", "published_display": "08 Mar 2026 22:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sponsor overpayment leads to CEO change at Drugs Made In America II (DMII)", "summary": "Drugs Made In America Acquisition II Corp. (DMII) experienced a significant leadership change due to a sponsor overpayment issue. The sponsor withdrew $1,100,000 from the company's working capital, with a substantial portion ($566,269 plus at least $200,000) identified as an over", "url": "https://www.stocktitan.net/sec-filings/DMII/8-k-drugs-made-in-america-acquisition-ii-corp-reports-material-event-3355793bd262.html", "source_name": "Stock Titan", "published_at": "2026-03-07T21:52:39", "published_display": "07 Mar 2026 21:52", "sentiment": "negative", "sentiment_pct": 15, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMIIR Stock Price, Quote & Chart | DRUGS MADE IN AMERICA ACQ-RT (NASDAQ:DMIIR)", "summary": "DRUGS MADE IN AMERICA ACQ-RT (NASDAQ:DMIIR) shares closed at $0.09, down 18.18% today, and are trading at $0.13 after hours, up 44.44%. The company, a blank check company focused on the pharmaceutical industry, has seen its stock decline by 25% over the past month. ChartMill assi", "url": "https://www.chartmill.com/stock/quote/DMIIR/profile", "source_name": "ChartMill", "published_at": "2026-03-07T21:51:39", "published_display": "07 Mar 2026 21:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMII Stock Price and Chart \u2014 NASDAQ:DMII", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE0tei1fMmdvanZGOTBETzhMN2NIR3ZQYWNWSlJoZzQ5YlJPMm1GeHNBTDlZZzhfYWNIYlEtaEl0aXJjVXBROS1MejV4WG1XZi12ek5lRkc0OXJfbXRS?oc=5", "source_name": "TradingView", "published_at": "2025-12-03T14:58:38+00:00", "published_display": "03 Dec 2025 14:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tandem Diabetes (TNDM) Shares Are Plunging Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPaTRDbENXQUpyOGdxNlVEX19nN3hONEd1dkJYTjI2QWdjakw5RXlmV3dKb2NoLUVmOUpEMFJ2blhCSlI0clllVENfeVFxVk1jcVI3dXA1XzRZeWdrQ1RFd09ncG1yNkFCWHdxX2xIc2IwN0VDUk1fV1p5ZkhSeWQwNllMQQ?oc=5", "source_name": "Market source", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tandem Diabetes (TNDM) Shares Are Getting Obliterated Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxQVzltdXhxZmVkdmd1QXRKMTFNajROVUxHaFJTdU1MdEQ4dHNwYzRjMmpIdzdxWDlpWjFXb29kMl90UVRtWGFuM1JjY25aMGpMeGZOd0VWVzlKdURDclJwdEJHaDFxY3VlTWVONGZ1bXVHZGc2XzhJSUg1OTkxV2pZRy1RRQ?oc=5", "source_name": "Market source", "published_at": "2025-10-31T07:00:00+00:00", "published_display": "31 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II (DMIIU) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVEFVX3lxTFBGU2Y4dVVTM3gwWEJyem96UGtIbWZEelBIZ184NDMyNHNWTkxVc09ncnFWZUNEZDhuYmJZMVRaM0hiVUl1VUZhLWFmSWhJM2VpbFJJaQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-09-25T11:28:45+00:00", "published_display": "25 Sep 2025 11:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made in America Acquisition II Corp. (DMIIU) Prices $500M IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOVl8zb2FVdHBadk9yalpMR2h1LVNndlZzdFFlVEQwUlVQYzNHSzhGdGw4VGFIRUJPSHZUUFNzVlRVNVFjdTIxZ3JoMW1NYU1vejFETWhyRUUySFlPWHRoZkJxZGU3VXVtLVJYY0NxZGVMTWVMb1JIYmFMS2VoQnBETjEtNHhRbllIRWEwamgtTWh2ZG9zTlRfRlJPY3AtN1JVSTZrWXJFdU1jLU0wUUlv?oc=5", "source_name": "SPACInsider", "published_at": "2025-09-25T07:00:00+00:00", "published_display": "25 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition (DMAA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5va2pWcm8xT3NBTnQxNjJVUW0zck9FUXJHcGNSNjV3SV9RVHRpZlgybHRwY2hPVmdVTy0zbUY5aFZBazhsUTR2X1VoWG1WbnRJS3RfOXRMd1JOZw?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-24T23:55:47+00:00", "published_display": "24 Jul 2025 23:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cannabis Giant's $3.5 Billion Transformation: From Bright Green to 'Drugs Made in America'", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOcVFURmUzZl82WHJldlpfOEZuVVV6a3I0bjRKdE14a2hieVFtYXRRYTRzVGxQVGx4RDRyZFVhT09YSHg2NHUwaEpqOUVLN2FwNXQ5UER1NmlkblptcHByc29Xd1A5N2hJcUdid2Z6dmxUNUZza2d6UmQ5alZmMHJmN3gyOWhqb2VSa2o0dHo4M2h2a1I3YmxLbC1NV1RUM0x3blBzTVZuTUxfalRiOHUzcm11OV8?oc=5", "source_name": "Stock Titan", "published_at": "2025-01-27T08:00:00+00:00", "published_display": "27 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Drugs Made In America Acquisition (NASDAQ:DMAA) Trading Down 0.1% - Here's What Happened", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNM2FXbkJYaDJZeGhjU3VrelVXa3NHZ2dSam16MzYzNk1QdmRsbU1WSmNTbU1oX2tuTWRLaFFxWG1TYmFlMDNqVW5UOFlHTFgyQU1EQWowZ2xRUjJuVmlCdVd3SXVSOHhSWXBNRTFWXzFQdTdBZEF1WjFmMldJekwycWRyWXB0akd6YVlEd2JjSnB4TG1EXzVvazUxRnFsTW43TWlOc2tpdE51dm5lajdyOGkzaHJDNFFoeEFLUnNNS3NXWFN2SWZXMTM3RmlkVWM?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-11T13:28:09+00:00", "published_display": "11 Jul 2026 13:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Drugs Made In America Acquisition Corp. \u2013 NASDAQ:DMAAR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPTjBjZHNSTFJCN2M5TFBmNzJvN1Fjc04yVTgzcjhra2RRd0U0STNZb1NwVkFDTXR1NmRNRVl1MnJndVptRUt2UFh3ekxkZmxsOWY5QmZ3VDNYV1ZGV1FEc0hJb0s1Y3h1WWQ2UGtqWTdOUzJXT1ZtMElZbTU4emxmc25fTXZ4QTc5cm9Bd25FUjVnYjV5eHF3THVfTlVWNy1iRndz?oc=5", "source_name": "TradingView", "published_at": "2026-07-07T02:32:22+00:00", "published_display": "07 Jul 2026 02:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tandem Diabetes (TNDM) Shares Are Sliding Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOX3pyOWxmc05WS1NBdmV3anVMRG9OSkd1OU1RNnFCVWkxcTVtdWRWTG1jVERPaVExQlZaa09kdWNCZHk2a3JjUFpfVmpvSEptVUFXV3JLYWVjWnY0UVdXTUJCR2UzYTV6ODFyVUNhNE5raDBTelhSNmF4ZExCazdURjctU05mdkh3LUpXUC10dmgwUDZZUkN3eFlKWFUzNUk1dTNicTVIRnZkUV9EUF9j?oc=5", "source_name": "TradingView", "published_at": "2026-06-30T18:56:21+00:00", "published_display": "30 Jun 2026 18:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Drugs Made In America Acquisition II Corp. \u2013 NASDAQ:DMII", "summary": "The article focuses on the \"Price to sales forward\" metric for Drugs Made In America Acquisition II Corp. (NASDAQ: DMII). It provides basic financial and market information for the company, indicating that the market is currently closed with no trades. The content appears to be a", "url": "https://www.tradingview.com/symbols/NASDAQ-DMII/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T13:11:57", "published_display": "29 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMII Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article provides a financial overview of Drugs Made In America Acquisition II Corp (DMII), detailing its profitability ratios, including Return on Equity, and comparing its market capitalization with competitors like RMR and BCSS. It notes that DMII's gross, operating, and n", "url": "https://intellectia.ai/en/stock/DMII/financials", "source_name": "Intellectia AI", "published_at": "2026-06-27T22:10:05", "published_display": "27 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Drugs Made In America Acquisition II Corp. \u2013 NASDAQ:DMIIR", "summary": "This article provides financial information for Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR), specifically focusing on its price-to-book forward ratio. The content appears to be a stub or a section from a larger financial data platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-DMIIR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T12:08:54", "published_display": "26 Jun 2026 12:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tandem Diabetes (NASDAQ: TNDM) Rule 144 notice to sell 361 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQUkdpSjdvbTZBNnd4Yng4T1hjdWhNdnROUU9FeEE3MTlUNGZIRldsc1ZEX3loWEJWaWNVQzBFVXdCak5HUWxDOEF1M2J5LThZeWFCUlBya04xSjlwRXVrWmlTM244ZTJxeXN1MG9Qal9RalVMRDYyZnJRWk1pamZ1dHVPT1haVlZjUGhGeW1DUng1UWxCUUJRNjlXOW5OT0lIRlJ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. (DMII) Holds Steady Near $10.07, Trading in Tight Range - Risk Parity Rebalance", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQVG5UMmJucUJ2TXdwaUszQkJXZWNteEs1N2JIVm40UDFDVjNBcDRIVE8xYl9hV0pCVGtWSTdSUmZuVnBWbHA1S0RNUTh4R2xMb3ByY3JnTVE4Z1h3VWkxcXcwQlU2UUJhYUNlWGRTcFNTVjlJVEhyc1dPTzhfcDVScDIxMEpRMnZjMlpMWndTU2c4YWk5UnFwRWw1REJTdTUzV3h4eTZ6ZmhmSUZGeDlBTi1kM1ZHS0UweUpwZkV6M3UyYWlNcjN6YTUxR3hsUFBDMHMtMXpnVzBoc0ph?oc=5", "source_name": "B\u00f6l\u00fcm Sonu Canavar\u0131", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. Unit (DMIIU) Holds Steady Amid Extended Consolidation - Money Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQZlpGX3d3N3ZScDNVQXlwbzVfVEp0RmZxMjh1TlU5TFRHY2hXVUVlVkJyeEQwQ3AtZmtLRllfcUZTYUk1MUNzdDd5Y29GeF9zSUpNbkVrTWxNelcyVGpHd1JiM1pZb0FzVXU4UDZYb1dIUGtvMkMxQ3FVSHdDc3RncFFGYnJkZkUzVFhyOVJCdzdTODNSV3h4cDdGTFd2MkNDVTd2TW5MTVZySGpGcVVaMkw4WHRTQmJOemtjLWlTN1F0LWlFQTUtUi1BYlFzZFc5WEE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HEIGHTS CAPITAL MANAGEMENT, INC's Drugs Made In America Acquisition II Corp(DMIIU) Holding History", "summary": "This article details HEIGHTS CAPITAL MANAGEMENT, INC's historical holdings in Drugs Made In America Acquisition II Corp (DMIIU). As of March 31, 2026, the firm holds 0 shares of DMIIU, having made one purchase and one sale of 519,400 shares each, resulting in an estimated gain of", "url": "https://www.gurufocus.com/guru-portfolio/HEIGHTS%20CAPITAL%20MANAGEMENT,%20INC/DMIIU", "source_name": "GuruFocus", "published_at": "2026-05-15T22:09:31", "published_display": "15 May 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tandem Diabetes (TNDM) Shares Are Trading Lower Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOTEY4U2JLc0E4T0hMcHV5R293WEhSTjNDb2xWSGg5X0hpSEsxVXJ4dzI4UmIyaEI5NU1seW1PcUllcVdPTG8zc2pGdFlvZDk4ZFJRWUZHRG9aSlNIeVBUVGhtVFlneFlYM1lMSnoxTHVvRVFDd005c3VjRFdlRTFPWEppTldPNmk5bzUxNVhta1BTTUg4NEIxUWNXZHltUzVVNHluSmRsU0pCQTR1TXR6Sk42dXpRTld6eUdJ?oc=5", "source_name": "StockStory", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition Updates Executive Compensation Agreements", "summary": "Drugs Made In America Acquisition II Corp. (DMII) has updated its executive compensation agreements. Saleem Elmasri, CFO, will now receive 175,000 ordinary shares, while Roger Bendelac, CEO, will receive a monthly salary of $4,500 and 250,000 ordinary shares upon a definitive agr", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1603715/drugs-made-in-america-acquisition-updates-executive-compensation-agreements/", "source_name": "The Globe and Mail", "published_at": "2026-04-29T23:09:57", "published_display": "29 Apr 2026 23:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America (NASDAQ: DMAA) details SPAC cash, LOI and risks", "summary": "Drugs Made In America Acquisition Corp. (DMAA), a SPAC, has filed its annual report detailing its search for a merger target. The company currently holds $231.15 million in its trust account and reported a net income of $5.94 million in 2025 from interest on these investments. DM", "url": "https://www.stocktitan.net/sec-filings/DMAA/10-k-drugs-made-in-america-acquisition-corp-files-annual-report-77c544c456a1.html", "source_name": "Stock Titan", "published_at": "2026-04-15T21:40:00", "published_display": "15 Apr 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II (DMII) logs $4.2M income, flags going-concern risk", "summary": "Drugs Made In America Acquisition II (DMII), a blank check company, reported a net income of $4.187 million for 2025, primarily from interest on its $500 million trust account investments. However, the company faces substantial doubt about its ability to continue as a going conce", "url": "https://www.stocktitan.net/sec-filings/DMII/10-k-drugs-made-in-america-acquisition-ii-corp-files-annual-report-db37da9991f3.html", "source_name": "Stock Titan", "published_at": "2026-04-15T20:08:51", "published_display": "15 Apr 2026 20:08", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. Auditor Raises 'Going Concern' Doubt", "summary": "Drugs Made In America Acquisition II Corp. (DMII) recently had its auditor, Malone & Bailey, PLLC, express doubt about the company's ability to continue as a going concern. This assessment was made after the company filed its 10-K report on April 15, 2026, for the fiscal year end", "url": "https://www.marketscreener.com/news/drugs-made-in-america-acquisition-ii-corp-auditor-raises-going-concern-doubt-ce7f59dedc8ef422", "source_name": "www.marketscreener.com", "published_at": "2026-04-12T19:10:17", "published_display": "12 Apr 2026 19:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made in America Acquisition Corp. signs LOI for de-SPAC with Power Analytics", "summary": "Drugs Made in America Acquisition Corp. (NASDAQ:DMAA) announced it has signed a letter of intent for a de-SPAC transaction with Power Analytics Global Corp., valuing the target company at approximately $1.0 billion. The transaction is subject to further negotiation and due dilige", "url": "https://www.investing.com/news/sec-filings/drugs-made-in-america-acquisition-corp-signs-loi-for-despac-with-power-analytics-93CH-4603239", "source_name": "Investing.com", "published_at": "2026-04-09T09:12:00", "published_display": "09 Apr 2026 09:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. Unit (DMIIU) Competitors", "summary": "This article provides a detailed comparison of Drugs Made In America Acquisition II Corp. Unit (DMIIU) with numerous competitors in the Financial Services sector. It presents a peer comparison table with financial metrics like price, market cap, P/E ratio, EPS, and dividend yield", "url": "https://meyka.com/stock/DMIIU/peers/", "source_name": "Meyka", "published_at": "2026-04-09T01:09:11", "published_display": "09 Apr 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. enters $300,000 convertible note agreement", "summary": "Drugs Made In America Acquisition II Corp. (DMIIU, DMII, DMIIR) has entered into a $300,000 interim convertible note agreement with Alpha Multi Family Office, carrying no interest and maturing in nine months. This note allows Alpha Multi Family Office to convert the principal int", "url": "https://ca.investing.com/news/sec-filings/drugs-made-in-america-acquisition-ii-corp-enters-300000-convertible-note-agreement-93CH-4549250", "source_name": "Investing.com Canada", "published_at": "2026-04-04T22:39:18", "published_display": "04 Apr 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. Announces $1.4 Million Convertible Notes Financing Agreement with Alpha Multi Family Office", "summary": "Drugs Made In America Acquisition II Corp. has secured a $1.4 million convertible notes financing agreement from S.E.E Capitals Ltd., with the funds allocated for operational and regulatory costs. The agreement includes provisions for potential share dilution if the investor conv", "url": "https://www.minichart.com.sg/2026/04/04/drugs-made-in-america-acquisition-ii-corp-announces-1-4-million-convertible-notes-financing-agreement-with-alpha-multi-family-office/", "source_name": "Minichart", "published_at": "2026-04-04T22:09:34", "published_display": "04 Apr 2026 22:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America II Issues Interim Convertible Note", "summary": "Drugs Made In America Acquisition II Corp. (DMII) has issued a new $300,000 interim convertible note on March 30, 2026, building upon a previous $150,000 bridge note from March 11, 2026, as part of a $1.4 million financing plan. This new note, maturing in nine months with no inte", "url": "https://www.tipranks.com/news/company-announcements/drugs-made-in-america-ii-issues-interim-convertible-note", "source_name": "TipRanks", "published_at": "2026-04-03T21:12:55", "published_display": "03 Apr 2026 21:12", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Finalizes $1.4M Notes Deal, Adds $300K Interim Convertible", "summary": "Drugs Made In America Acquisition II (DMII) has finalized a definitive agreement with Alpha Multi Family Office for a $1.4 million convertible notes financing. Concurrently, it issued a new $300,000 interim convertible note to provide immediate liquidity. Both agreements aim to s", "url": "https://www.tradingview.com/news/tradingview:9badd5a98b635:0-drugs-made-in-america-acquisition-ii-finalizes-1-4m-notes-deal-adds-300k-interim-convertible/", "source_name": "TradingView", "published_at": "2026-04-03T20:42:55", "published_display": "03 Apr 2026 20:42", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$300K zero\u2011interest note backs Drugs Made In America II (NASDAQ: DMII)", "summary": "Drugs Made In America Acquisition II Corp. (DMII) secured a new $300,000 zero-interest Interim Convertible Note from Alpha Multi Family Office, part of a contemplated $1.4 million financing. This note matures in nine months and can convert into shares at a 35% discount post-merge", "url": "https://www.stocktitan.net/sec-filings/DMII/8-k-drugs-made-in-america-acquisition-ii-corp-reports-material-event-602970d519a7.html", "source_name": "Stock Titan", "published_at": "2026-04-03T20:39:55", "published_display": "03 Apr 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made in America Acquisition II Delays Annual Filing", "summary": "Drugs Made in America Acquisition II Corp. (DMII) has announced a delay in filing its Form 10-K for the fiscal year ended December 31, 2025, due to complexities in compiling required financial statements. The company anticipates filing by April 15, 2026, and does not foresee sign", "url": "https://www.tipranks.com/news/company-announcements/drugs-made-in-america-acquisition-ii-delays-annual-filing", "source_name": "TipRanks", "published_at": "2026-04-01T23:39:58", "published_display": "01 Apr 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMII (NASDAQ: DMII) files 12b-25\u2014expects to file 10-K by Apr 15, 2026", "summary": "Drugs Made in America Acquisition II Corp. (DMII) has filed a Form 12b-25 with the SEC, indicating that it will be submitting its Form 10-K for the fiscal year ended December 31, 2025, later than the due date. The company stated that compiling the required financial statements an", "url": "https://www.stocktitan.net/sec-filings/DMII/nt-10-k-drugs-made-in-america-acquisition-ii-corp-sec-filing-1ea9598c3e77.html", "source_name": "Stock Titan", "published_at": "2026-04-01T20:11:11", "published_display": "01 Apr 2026 20:11", "sentiment": "negative", "sentiment_pct": 37, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. - Right (NQ: DMIIR)", "summary": "This article provides a brief overview of Drugs Made In America Acquisition II Corp. - Right (DMIIR) stock, including its current price, trading volume, and performance metrics. It lists the stock at $0.0800, unchanged, with its last trade recorded on April 1, 2026, at 3:20 PM ED", "url": "https://markets.financialcontent.com/stocks/quote?Symbol=537%3A2578439971", "source_name": "FinancialContent", "published_at": "2026-04-01T19:39:59", "published_display": "01 Apr 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Drugs Made In America Acquisition II Corp. Unit (DMIIU) Stock Down Today?", "summary": "Drugs Made In America Acquisition II Corp. Unit (DMIIU) stock is currently down -0.10% at $10.02, indicating a negative investor sentiment. The stock is trading below both its 50-day and 200-day moving averages, suggesting short-term and long-term weakness. Meyka's AI assigns DMI", "url": "https://meyka.com/stock/DMIIU/why-stock-down-today/", "source_name": "Meyka", "published_at": "2026-03-24T11:08:58", "published_display": "24 Mar 2026 11:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) Stock Down Today?", "summary": "Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) stock is down 0.10% today, trading at $9.96 with significantly lower than average trading volume. The stock is below its 50-day moving average but above its 200-day moving average, suggesting short-term weakness bu", "url": "https://meyka.com/stock/DMII/why-stock-down-today/", "source_name": "Meyka", "published_at": "2026-03-23T21:08:58", "published_display": "23 Mar 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "14,375,000 Ordinary Shares of Drugs Made In America Acquisition II Corp. are subject to a Lock-Up Agreement Ending on 23-MAR-2026.", "summary": "Approximately 14,375,000 ordinary shares of Drugs Made In America Acquisition II Corp. (DMII) are subject to a lock-up agreement that expires on March 23, 2026. This lock-up period began on September 24, 2025, and restricts the sale or transfer of these shares by the company's sp", "url": "https://www.marketscreener.com/news/14-375-000-ordinary-shares-of-drugs-made-in-america-acquisition-ii-corp-are-subject-to-a-lock-up-ag-ce7e5edcdb8cf72d", "source_name": "www.marketscreener.com", "published_at": "2026-03-23T00:10:39", "published_display": "23 Mar 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMII Stock Price, News & Analysis", "summary": "Drugs Made In Amer Acq Ii (DMII) is a blank check company listed on NASDAQ with a market capitalization of $653.1M. The stock last traded at $9.96, showing a 0.8% gain over the past year. Recent SEC filings include a planned $1.4M convertible note funding and a CEO change due to ", "url": "https://www.stocktitan.net/overview/DMII/", "source_name": "Stock Titan", "published_at": "2026-03-18T18:39:23", "published_display": "18 Mar 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prudential Earnings: Headline Numbers Make the Market Skeptical; Shares Fairly Valued", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOLXpWLThmYURNcnJBLXZQNTlRUy1NSmQ4NkVVX0pQRzlfUFFtVFJkNDJqN1FFYWZLWS1xSmd5S3dNUU42cjFLOUdiWTkxdXhvZXg1UlFtZmtVZG1qN2w4QWxXZEJsbFJ2QUQtVUIxMWJ4Z1l3djBiNFp3MEdhbkh6cUtlWVB5b2RNZXZudmhPbWI3RkF0NmhxdF9aQmppbUFHOThtZDlBU3Vsak9fX0pKUGotdHNBaDkzODRZbGdUUVc?oc=5", "source_name": "Morningstar", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America II (NASDAQ: DMII) plans $1.4M convertible note funding", "summary": "Drugs Made In America Acquisition II Corp. (NASDAQ: DMII) has entered into an agreement for up to $1.4 million in convertible note funding with Alpha Multi Family Office. The initial tranche involved an unsecured, zero-interest Bridge Note for $150,000, convertible at a 35% disco", "url": "https://www.stocktitan.net/sec-filings/DMII/8-k-drugs-made-in-america-acquisition-ii-corp-reports-material-event-0798a7bf46b6.html", "source_name": "Stock Titan", "published_at": "2026-03-18T03:09:55", "published_display": "18 Mar 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Secures $150,000 Convertible Bridge Note From Alpha Multi Family Office", "summary": "Drugs Made In America Acquisition II (DMII) has secured a $150,000 unsecured convertible bridge note from Alpha Multi Family Office to cover near-term transaction costs. The nine-month, zero-interest note can convert into post-combination company shares at a 35% discount upon bus", "url": "https://www.tradingview.com/news/tradingview:7e76831afc085:0-drugs-made-in-america-acquisition-ii-secures-150-000-convertible-bridge-note-from-alpha-multi-family-office/", "source_name": "TradingView", "published_at": "2026-03-17T20:09:55", "published_display": "17 Mar 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMIIR - AI Stock Analysis", "summary": "This article provides an AI-powered stock analysis for Drugs Made In America Acquisition II Corp. Right (DMIIR). The AI model gives DMIIR an overall forecast score of 51/100 (C+), indicating normal performance with weak confidence in its potential. While its financial and fundame", "url": "https://meyka.com/stock/DMIIR/analysis/", "source_name": "Meyka", "published_at": "2026-03-16T03:39:23", "published_display": "16 Mar 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II Corp. appoints new CEO after sponsor repayment issue", "summary": "Drugs Made In America Acquisition II Corp. (NASDAQ:DMIIU) has appointed Roger Bendelac as its new CEO, following the resignation of Lynn Stockwell. Stockwell's resignation was requested after the company discovered its sponsor had over-withdrawn funds from the working capital acc", "url": "https://www.investing.com/news/sec-filings/drugs-made-in-america-acquisition-ii-corp-appoints-new-ceo-after-sponsor-repayment-issue-93CH-4547284", "source_name": "Investing.com", "published_at": "2026-03-08T22:51:22", "published_display": "08 Mar 2026 22:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO exits Drugs Made In America (NASDAQ: DMAA) after affiliate fund withdrawals", "summary": "Drugs Made In America Acquisition Corp. (DMAA) announced the resignation of CEO Lynn Stockwell and the appointment of Roger Bendelac following financial discrepancies involving an affiliated SPAC's working capital account. The affiliate's sponsor withdrew $1,100,000 and had an ov", "url": "https://www.stocktitan.net/sec-filings/DMAA/8-k-drugs-made-in-america-acquisition-corp-reports-material-event-100e6bb0dc73.html", "source_name": "Stock Titan", "published_at": "2026-03-08T22:51:22", "published_display": "08 Mar 2026 22:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sponsor overpayment leads to CEO change at Drugs Made In America II (DMII)", "summary": "Drugs Made In America Acquisition II Corp. (DMII) experienced a significant leadership change due to a sponsor overpayment issue. The sponsor withdrew $1,100,000 from the company's working capital, with a substantial portion ($566,269 plus at least $200,000) identified as an over", "url": "https://www.stocktitan.net/sec-filings/DMII/8-k-drugs-made-in-america-acquisition-ii-corp-reports-material-event-3355793bd262.html", "source_name": "Stock Titan", "published_at": "2026-03-07T21:52:39", "published_display": "07 Mar 2026 21:52", "sentiment": "negative", "sentiment_pct": 15, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMIIR Stock Price, Quote & Chart | DRUGS MADE IN AMERICA ACQ-RT (NASDAQ:DMIIR)", "summary": "DRUGS MADE IN AMERICA ACQ-RT (NASDAQ:DMIIR) shares closed at $0.09, down 18.18% today, and are trading at $0.13 after hours, up 44.44%. The company, a blank check company focused on the pharmaceutical industry, has seen its stock decline by 25% over the past month. ChartMill assi", "url": "https://www.chartmill.com/stock/quote/DMIIR/profile", "source_name": "ChartMill", "published_at": "2026-03-07T21:51:39", "published_display": "07 Mar 2026 21:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DMII Stock Price and Chart \u2014 NASDAQ:DMII", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE0tei1fMmdvanZGOTBETzhMN2NIR3ZQYWNWSlJoZzQ5YlJPMm1GeHNBTDlZZzhfYWNIYlEtaEl0aXJjVXBROS1MejV4WG1XZi12ek5lRkc0OXJfbXRS?oc=5", "source_name": "TradingView", "published_at": "2025-12-03T14:58:38+00:00", "published_display": "03 Dec 2025 14:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tandem Diabetes (TNDM) Shares Are Plunging Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPaTRDbENXQUpyOGdxNlVEX19nN3hONEd1dkJYTjI2QWdjakw5RXlmV3dKb2NoLUVmOUpEMFJ2blhCSlI0clllVENfeVFxVk1jcVI3dXA1XzRZeWdrQ1RFd09ncG1yNkFCWHdxX2xIc2IwN0VDUk1fV1p5ZkhSeWQwNllMQQ?oc=5", "source_name": "Market source", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tandem Diabetes (TNDM) Shares Are Getting Obliterated Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxQVzltdXhxZmVkdmd1QXRKMTFNajROVUxHaFJTdU1MdEQ4dHNwYzRjMmpIdzdxWDlpWjFXb29kMl90UVRtWGFuM1JjY25aMGpMeGZOd0VWVzlKdURDclJwdEJHaDFxY3VlTWVONGZ1bXVHZGc2XzhJSUg1OTkxV2pZRy1RRQ?oc=5", "source_name": "Market source", "published_at": "2025-10-31T07:00:00+00:00", "published_display": "31 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition II (DMIIU) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVEFVX3lxTFBGU2Y4dVVTM3gwWEJyem96UGtIbWZEelBIZ184NDMyNHNWTkxVc09ncnFWZUNEZDhuYmJZMVRaM0hiVUl1VUZhLWFmSWhJM2VpbFJJaQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-09-25T11:28:45+00:00", "published_display": "25 Sep 2025 11:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made in America Acquisition II Corp. (DMIIU) Prices $500M IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOVl8zb2FVdHBadk9yalpMR2h1LVNndlZzdFFlVEQwUlVQYzNHSzhGdGw4VGFIRUJPSHZUUFNzVlRVNVFjdTIxZ3JoMW1NYU1vejFETWhyRUUySFlPWHRoZkJxZGU3VXVtLVJYY0NxZGVMTWVMb1JIYmFMS2VoQnBETjEtNHhRbllIRWEwamgtTWh2ZG9zTlRfRlJPY3AtN1JVSTZrWXJFdU1jLU0wUUlv?oc=5", "source_name": "SPACInsider", "published_at": "2025-09-25T07:00:00+00:00", "published_display": "25 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drugs Made In America Acquisition (DMAA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5va2pWcm8xT3NBTnQxNjJVUW0zck9FUXJHcGNSNjV3SV9RVHRpZlgybHRwY2hPVmdVTy0zbUY5aFZBazhsUTR2X1VoWG1WbnRJS3RfOXRMd1JOZw?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-24T23:55:47+00:00", "published_display": "24 Jul 2025 23:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cannabis Giant's $3.5 Billion Transformation: From Bright Green to 'Drugs Made in America'", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOcVFURmUzZl82WHJldlpfOEZuVVV6a3I0bjRKdE14a2hieVFtYXRRYTRzVGxQVGx4RDRyZFVhT09YSHg2NHUwaEpqOUVLN2FwNXQ5UER1NmlkblptcHByc29Xd1A5N2hJcUdid2Z6dmxUNUZza2d6UmQ5alZmMHJmN3gyOWhqb2VSa2o0dHo4M2h2a1I3YmxLbC1NV1RUM0x3blBzTVZuTUxfalRiOHUzcm11OV8?oc=5", "source_name": "Stock Titan", "published_at": "2025-01-27T08:00:00+00:00", "published_display": "27 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 102, "total_relevant": 44, "sentiment_summary": {"positive": 3, "negative": 8, "neutral": 33, "score": 47, "total": 44, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "deals", "primary_label": "Deals and strategy", "confidence": 87, "events": [{"event": "deals", "label": "Deals and strategy", "weight": 18.7, "count": 34}, {"event": "general", "label": "Market update", "weight": 4.95, "count": 9}, {"event": "earnings", "label": "Earnings", "weight": 0.9, "count": 1}], "positive_events": 3, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 10.1, "latest_week": "2026-07-10", "one_week_move": 0.1, "four_week_move": 0.2, "twelve_week_move": 0.9, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.111235, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": 1.1, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 54.1176, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.1% over one week, +0.2% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 54, "badges": [], "opportunities": [], "risks": [], "event_label": "Deals and strategy", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "TradingView", "count": 7}, {"label": "Meyka", "count": 4}, {"label": "MarketBeat", "count": 2}, {"label": "www.marketscreener.com", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "TipRanks", "count": 2}, {"label": "Market source", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 44}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Deals and strategy", "count": 34}, {"label": "Market update", "count": 9}, {"label": "Earnings", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "47/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Deals and strategy", "tone": "neutral", "text": "87/100 classification confidence."}, {"label": "Company focus", "value": "44", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.1% over one week, +0.2% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Drugs Made In America Acquisition (NASDAQ:DMAA) Trading Down 0.1% - Here's What Happened"}], "updated_at": "2026-07-16T08:15:58.321449+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}